http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110064046-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110064046-B |
| titleOfInvention | Application of micropeptide YY1BM in the treatment of cancer |
| abstract | The present invention relates to the application of micropeptide YY1BM in the treatment of cancer. From the perspective of micropeptide encoded by lncRNA at the translation level, the effect of micropeptide on apoptosis of esophageal squamous cell carcinoma is studied, and the effect of micropeptide on esophageal squamous cell carcinoma is proved. important role in. Moreover, the micropeptide YY1BM induces the apoptosis of male esophageal squamous cell carcinoma cells, changes the expression of the micropeptide, blocks the interaction between YY1 and AR, inhibits the transcription of eEF2K, and then promotes the activity of eEF2, leading to ESCC apoptosis and This achieves the effect of treating ESCC. Moreover, targeted therapy through micropeptide YY1BM can up-regulate the expression of micropeptide YY1BM, which has clinical medicinal value for male esophageal squamous cell carcinoma. |
| priorityDate | 2019-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 119.